Literature DB >> 26426381

NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.

Daniel Martinez1, Alba Navarro, Alejandra Martinez-Trillos, Ricardo Molina-Urra, Blanca Gonzalez-Farre, Itziar Salaverria, Ferran Nadeu, Anna Enjuanes, Guillem Clot, Dolors Costa, Ana Carrio, Neus Villamor, Dolors Colomer, Antonio Martinez, Susanne Bens, Reiner Siebert, Andrew Wotherspoon, Sílvia Beà, Estella Matutes, Elias Campo.   

Abstract

Splenic diffuse red pulp small B-cell lymphoma (SDRPL) is considered an indolent neoplasm and its pathogenesis is not well known. We investigated the molecular characteristics of 19 SDRPL patients, 5 of them with progressive disease. IGHV genes were mutated in 9/13 (69%). Cytogenetic and molecular studies identified complex karyotypes in 2 cases, and IGH rearrangements in 3, with PAX5 and potentially TCL1 as partners in each one of them. Copy number arrays showed aberrations in 69% of the tumors, including recurrent losses of 10q23, 14q31-q32, and 17p13 in 3, and 9p21 in 2 cases. Deletion of 7q31.3-q32.3 was present in only 1 case and no trisomies 3 or 18 were detected. NOTCH1 and MAP2K1 were mutated in 2 cases each, whereas BRAF, TP53, and SF3B1 were mutated each in single cases. No mutations were found in NOTCH2 or MYD88. Four of the 5 patients with aggressive disease had mutations in NOTCH1 (2 cases), TP53 (1 case), and MAP2K1 (1 case). The progression-free survival of patients with mutated genes was significantly shorter than in the unmutated (P=0.011). These findings show that SDRPL share some mutated genes but not chromosomal alterations, with other splenic lymphomas, that may confer a more aggressive behavior.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26426381     DOI: 10.1097/PAS.0000000000000523

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up.

Authors:  Helen Parker; Neil Robert McIver-Brown; Zadie A Davis; Marina Parry; Matthew J J Rose-Zerilli; Aliki Xochelli; Jane Gibson; Renata Walewska; Jonathan C Strefford; David G Oscier
Journal:  Blood Adv       Date:  2018-05-22

2.  Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.

Authors:  Janine Schmidt; Joan Enric Ramis-Zaldivar; Ferran Nadeu; Blanca Gonzalez-Farre; Alba Navarro; Caoimhe Egan; Ivonne Aidee Montes-Mojarro; Teresa Marafioti; Jose Cabeçadas; Jon van der Walt; Stefan Dojcinov; Andreas Rosenwald; German Ott; Irina Bonzheim; Falko Fend; Elias Campo; Elaine S Jaffe; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood       Date:  2017-05-22       Impact factor: 22.113

3.  Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.

Authors:  Yi Wang; Tingyu Wang; Ying Yu; Qi Wang; Yuting Yan; Ru Li; Qi Sun; Wenjie Xiong; Rui Lyu; Zhen Yu; Wei Liu; Weiwei Sui; Wenyang Huang; Huijun Wang; Chengwen Li; Jun Wang; Dehui Zou; Gang An; Jianxiang Wang; Lugui Qiu; Shuhua Yi
Journal:  Ann Hematol       Date:  2022-04-18       Impact factor: 3.673

Review 4.  The Varied Roles of Notch in Cancer.

Authors:  Jon C Aster; Warren S Pear; Stephen C Blacklow
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

5.  Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier.

Authors:  Alba Navarro; Guillem Clot; Alejandra Martínez-Trillos; Magda Pinyol; Pedro Jares; Blanca González-Farré; Daniel Martínez; Nicola Trim; Verónica Fernández; Neus Villamor; Dolors Colomer; Dolors Costa; Itziar Salaverria; David Martín-Garcia; Wendy Erber; Cristina López; Sandrine Jayne; Reiner Siebert; Martin J S Dyer; Adrian Wiestner; Wyndham H Wilson; Marta Aymerich; Armando López-Guillermo; Àlex Sánchez; Elías Campo; Estella Matutes; Sílvia Beà
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941

6.  Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.

Authors:  Laurent Jallades; Lucile Baseggio; Pierre Sujobert; Sarah Huet; Kaddour Chabane; Evelyne Callet-Bauchu; Aurélie Verney; Sandrine Hayette; Jean-Pierre Desvignes; David Salgado; Nicolas Levy; Christophe Béroud; Pascale Felman; Françoise Berger; Jean-Pierre Magaud; Laurent Genestier; Gilles Salles; Alexandra Traverse-Glehen
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

7.  A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children.

Authors:  Leyuan Wang; Lin Yuan; Xizi Du; Kai Zhou; Yu Yang; Qingwu Qin; Liangchun Yang; Yang Xiang; Xiangping Qu; Huijun Liu; Xiaoqun Qin; Chi Liu
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

Review 8.  The Genomics of Hairy Cell Leukaemia and Splenic Diffuse Red Pulp Lymphoma.

Authors:  David Oscier; Kostas Stamatopoulos; Amatta Mirandari; Jonathan Strefford
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

Review 9.  KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.

Authors:  Elena Vendramini; Riccardo Bomben; Federico Pozzo; Tamara Bittolo; Erika Tissino; Valter Gattei; Antonella Zucchetto
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

Review 10.  A Review on Splenic Diffuse Red Pulp Small B-Cell Lymphoma.

Authors:  Elif Yilmaz; Arashpreet Chhina; Victor E Nava; Anita Aggarwal
Journal:  Curr Oncol       Date:  2021-12-06       Impact factor: 3.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.